SPPL-2-C (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-SPPL2C
In stock
- SKU
- REC-SPPL2C
Target Overview
SPPL2C (Signal Peptide Peptidase-Like 2C, UniProt Q8IUH8) is a 684-amino-acid intramembrane-cleaving aspartic protease (I-CLiP) resident in the endoplasmic reticulum membrane. It belongs to the GxGD-type aspartic protease family, which also includes SPP, SPPL2A, and SPPL2B, and carries the conserved catalytic YD and GxGD motifs embedded within its transmembrane core. Unlike its close paralogs, SPPL2C shows markedly restricted tissue expression, with highest levels detected in testis — specifically in elongated spermatids — making it the focus of spermatogenesis research rather than broad immune or neurological studies. This recombinant is produced in HEK293 cells, an expression system that supports the complex multi-pass transmembrane topology and post-translational processing characteristic of GxGD proteases. HEK293-derived material retains mammalian glycosylation patterns relevant to proper folding and catalytic competence, and is suitable for use in detergent-solubilised or reconstituted membrane assay formats. Researchers employ this recombinant in substrate cleavage assays using tail-anchored protein or SNARE-derived substrates, in inhibitor IC50 determinations benchmarked against SPP/SPPL family pharmacology, and in selectivity profiling across SPPL family members. Because SPPL2C activity toward phospholamban (PLN) has been linked to intracellular Ca²⁺ homeostasis in spermatids, the recombinant is also used in calcium-signalling pathway studies in a cell-free format. Researchers requiring an antigen standard for Western blot or IHC validation of anti-SPPL2C antibodies can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-SPPL2C), which is validated for both applications against human target.
Background
Applications
- Intramembrane cleavage (I-CLiP) activity assay using SNARE-derived or tail-anchored peptide substrates in detergent-solubilised membrane reconstitution format
- Inhibitor IC50 determination and selectivity profiling across SPP/SPPL family members (e.g., (Z-LL)₂-ketone, DAPT, compound benchmarking)
- Substrate identification by co-incubation and mass spectrometry-based cleavage-site mapping
- PA domain contribution analysis via recombinant domain-swap or truncation construct comparison
- Western blot positive-control standard for anti-SPPL2C antibody validation (paired with TPB antibody SKU: RP-SPPL2C)
- IHC antigen standard for validating SPPL2C immunostaining protocols in testis tissue sections
- Calnexin–SPPL2C binding and chaperone-regulation studies by co-immunoprecipitation or surface plasmon resonance
- Recombinant antigen for SPPL2C antibody specificity confirmation in transcriptomic/proteomic expression-profiling validation workflows
References
- Schlosser C et al. The N-terminal PA domains of signal-peptide-peptidase-like 2 (SPPL2) proteases impact on TNFα cleavage. Commun Biol. 2025. doi: 10.1038/s42003-025-08102-y. PMID: 40307375.
- Contreras W et al. Selective regulation of aspartyl intramembrane protease activity by calnexin. Cell Mol Life Sci. 2024. doi: 10.1007/s00018-024-05478-8. PMID: 39460794.
- Welton T et al. Association of Gene Expression and Tremor Network Structure. Mov Disord. 2024. doi: 10.1002/mds.29831. PMID: 38769620.
- Shani S et al. MAPT Locus in Parkinson's Disease Patients of Ashkenazi Origin: A Stratified Analysis. Genes (Basel). 2023. doi: 10.3390/genes15010046. PMID: 38254936.
- Jung J. Identification of Breast Cancer Metastasis Markers from Gene Expression Profiles Using Machine Learning Approaches. Genes (Basel). 2023. doi: 10.3390/genes14091820. PMID: 37761960.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Multi-pass transmembrane; ER + Golgi; signal peptide peptidase-like |
Frequently Asked Questions
What molecular weight band should I expect for recombinant SPPL-2-C on SDS-PAGE or Western blot?
SPPL2C has a predicted molecular weight of approximately 75 kDa based on its 684-amino-acid sequence (UniProt Q8IUH8). However, because this recombinant is produced in HEK293 cells, N-linked glycosylation can shift the apparent MW on SDS-PAGE to 80–90 kDa depending on gel percentage and running conditions. We recommend a 10% polyacrylamide gel for clean resolution in this range. If you are running a positive control lane alongside RP-SPPL2C antibody validation, expect the broad band to land above the 75 kDa marker.
Is SPPL-2-C (Recombinant) the full-length protein or a processed catalytic fragment?
This recombinant represents the full-length 684-amino-acid SPPL2C sequence, including both the conserved catalytic YD and GxGD transmembrane motifs characteristic of GxGD-type intramembrane aspartic proteases. It is produced as an active enzyme in HEK293 cells and has not been truncated to an isolated luminal or cytoplasmic domain. The full-length form is relevant for topology-dependent activity assays and for researchers studying the complete multi-pass transmembrane architecture of SPPL2C in spermatogenesis contexts.
What substrates does SPPL-2-C cleave and how do I set up an intramembrane protease activity assay?
SPPL2C is an intramembrane-cleaving aspartic protease (I-CLiP) with substrate specificity overlapping but distinct from SPP, SPPL2A, and SPPL2B. Fluorogenic peptide substrates based on the SPP/SPPL consensus cleavage site (e.g., Boc-AIYLKATS-MCA or custom transmembrane-spanning peptides in detergent micelles) have been used for paralogous enzymes and represent a practical starting point. Activity assays should be performed in detergent-solubilized conditions using 0.1–0.5% DDM or CHAPSO at 37°C in 50 mM sodium acetate pH 6.5–7.0. Include pepstatin A as an aspartyl protease inhibitor control to confirm on-target activity.
What buffer and storage conditions are recommended for SPPL-2-C (Recombinant) activity assays?
The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For activity assays requiring a detergent-solubilized membrane environment, dilute the stock into assay buffer containing 0.1–0.5% CHAPSO or DDM before use — the glycerol carrier is compatible with these detergent systems at concentrations up to 2% in the final reaction. Store unused aliquots at -20°C; do not refreeze after thawing. Repeated freeze-thaw cycles measurably reduce intramembrane protease activity. Purity is >90% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL, so background from contaminant proteases is minimal.
What starting concentration of SPPL-2-C (Recombinant) should I use for an initial IC50 inhibitor screen?
For intramembrane aspartic protease inhibitor screens with fluorogenic substrates, a common starting point is 50–200 nM recombinant enzyme in the assay well. At these concentrations, signal-to-background ratios are typically sufficient without requiring excessive substrate. Keep final glycerol below 1% and detergent (CHAPSO or DDM) at 0.1–0.25% to avoid suppressing inhibitor binding. Include pepstatin A at 1 µM and an uninhibited vehicle control in each plate. Titrate enzyme concentration in a preliminary linearity experiment to confirm that activity is proportional to protein input before committing to a compound library screen.
Can I use recombinant SPPL-2-C as a positive control for Western blot with the RP-SPPL2C antibody?
Yes — REC-SPPL2C and the matched rabbit polyclonal RP-SPPL2C are validated together for exactly this use case. Load 50–200 ng of recombinant protein per lane alongside your cell lysate samples. Expect a band at approximately 80–90 kDa (glycosylated form) with RP-SPPL2C at a 1:500–1:2000 dilution in standard blocking buffer. Because the antibody and recombinant originate from the same development pipeline, this pairing provides a reliable positive control for antibody lot-to-lot validation, knockdown confirmation, and initial optimization of transfer conditions for this high-MW transmembrane target.
How much SPPL-2-C (Recombinant) should I load per lane when validating RP-SPPL2C antibody dilution series?
For a dilution-series validation of RP-SPPL2C, load a two-fold serial dilution of REC-SPPL2C across lanes: 200, 100, 50, 25, and 12.5 ng per lane. This range lets you determine the lower limit of detection for each antibody dilution tested (typically 1:500 to 1:5000). Run alongside 20–40 µg of testis or HEK293-overexpression lysate as an endogenous/transfected reference. Resolve on a 10% SDS-PAGE gel under reducing conditions. The recombinant's >90% purity means the dominant band at ~80–90 kDa cleanly represents SPPL2C without confounding cross-reactive bands from contaminants.
How should I handle and dilute SPPL-2-C (Recombinant) to avoid loss of activity after thawing?
Aliquots are supplied ready-to-use in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. Thaw on ice and use within the same working session. Do not refreeze. If you need to dilute for a lower working concentration, use the supplied storage buffer or an equivalent Tris/NaCl buffer supplemented with 0.05% BSA to minimize adsorptive losses at sub-nanomolar concentrations. For detergent-solubilized assays, add the appropriate detergent (DDM or CHAPSO) to the dilution buffer before adding protein. Shelf life is 12 months at -20°C in undisturbed single-use aliquots.
Validation imagery coming soon
Western blot validation figures for REC-SPPL2C will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.